Evaluation of plasma angiotensinogen(AGT) and the effect of DRI on AGT and RAAS in hemodialysis patients
Not Applicable
Recruiting
- Conditions
- Hemodialysis patients Hypertension
- Registration Number
- JPRN-UMIN000006479
- Lead Sponsor
- Kagawa University, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnancy 2.Severe hepatic or gallbladder disease (GOT > 150 IU or GPT > 150 IU) 3.Hyper potassium(k > 5.5 mEq/L) 4.Malignant tumor 5.Allergy to Aliskiren 6.During administration of itraconazole or ciclosporin 7.Other inadequacies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma AGT:0,2D,4D,7D,9D,11D,2,3,4,6,8W
- Secondary Outcome Measures
Name Time Method 1)BP:0,2D,4D,7D,9D,11D,2,3,4,6,8W 2)Plasma renin activity: 0,2D,4D,7D,9D,11D,2,3,4,6,8W Plasma renin concentration: 0,2D,4D,7D,9D,11D,2,3,4,6,8W 3)Plasma aldosterone:0,8W 4)proBNP:0,8W 5)Body Weight: 0,2D,4D,7D,9D,11D,2,3,4,6,8W 6)BUN, Cr:0,1,2,4,6,8W 7)Na, K, Cl, Ca, P:0,1,2,4,6,8W 8)CBC:0,1,2,4,6,8W